https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2009-11-25 14:01:412016-11-25 14:09:472009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1 Study
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2008-11-15 16:44:442016-11-25 16:45:042008 EORTC_In Vivo Activity of SGI-110, a Novel Hypomethylating Agent
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2008-08-25 14:10:082016-11-25 14:10:362008_A Dose Escalation, PK and PD Study of AT7519 in Patients with Refractory Solid Tumors
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2008-05-25 14:10:412016-11-25 14:11:072008 ASH_AT7519 is Active in CLL Patient Samples Independent of Stage
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-11-25 15:30:272016-11-25 15:30:482007 Gordon: Fragment Based Drug Design of AT13387 A Novel and Efficacious HSP90 Inhibitor
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-07-25 14:11:472016-11-25 14:12:322007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-04-25 14:12:422016-11-25 14:13:062007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines
